ARCHIMED Diagnostics, an EU-based healthcare firm specializing in diagnostics, has completed its acquisition of ARK Diagnostics, a U.S.-based leader in disease and drug monitoring and detection, for $428 million. The deal closed on October 28, 2025.
| Deal-at-a-glance | |
| Acquirer: | ARCHIMED Diagnostics (EU) |
|---|---|
| Target: | ARK Diagnostics (US) |
| Type: | Carve out |
| Closing Date: | 2025-10-28 |
| Deal Value: | $428m |
| Sell-side Advisors: | Not disclosed |
| Legal Buy-Side: | Archers, Slaughter and May |
Deal Mechanics
The acquisition enables ARCHIMED to expand its presence in the diagnostics sector. Soulbrain, a strategic partner of ARK Diagnostics, has reinvested a significant portion of its proceeds into a 40% stake in the company. Additionally, a joint venture agreement between ARCHIMED and Soulbrain was signed to accelerate ARK’s development.
Strategic Rationale
The rationale for this deal is to strengthen investment in diagnostics and support ARK's growth through strategic collaboration with Soulbrain. The partnership aims to bring together resources, technology, and expertise to enhance diagnostic capabilities globally.
Financial Context
This carve-out transaction reflects the growing importance of precision medicine and advanced diagnostics within the healthcare industry. With its strong financial backing from ARCHIMED and strategic alignment with Soulbrain, ARK is well-positioned to innovate in disease monitoring and drug detection technologies.
Outlook
The acquisition sets a positive trajectory for both companies involved. ARCHIMED's investment signals confidence in the future of diagnostic technology, while the joint venture between ARCHIMED and Soulbrain provides ARK with additional resources for research and development initiatives.